» Articles » PMID: 29124929

Injectable Polymeric Cytokine-Binding Nanowires Are Effective Tissue-Specific Immunomodulators

Overview
Journal ACS Nano
Specialty Biotechnology
Date 2017 Nov 11
PMID 29124929
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Injectable nanomaterials that interact with the host immune system without surgical intervention present spatially anchored complements to cell transplantation and could offer improved pharmacokinetics compared to systemic cytokine therapy. Here we demonstrate fabrication of high aspect ratio polycaprolactone nanowires coupled with cytokine-binding antibodies that assemble into porous matrices when injected into the subcutaneous space. These structures are fabricated using a nanotemplating technique that allows for tunability of particle dimensions and utilize a straightforward maleimide conjugation chemistry to allow site-specific coupling to proteins. Nanowires are well tolerated in vivo and incite minimal inflammatory infiltrate. Nanowires conjugated with antibodies were designed to capture and potentiate endogenous interleukin-2 (IL-2), an important leukocyte activating cytokine. Together these nanowire-antibody matrices were capable of localizing endogenous IL-2 in the skin and activated targeted specific natural killer and T cell subsets, demonstrating both tissue- and cell-specific immune activation. These self-assembling nanowire matrices show promise as scaffolds to present engineered, local receptor-ligand interactions for cytokine-mediated disease.

Citing Articles

Apical integrins as a switchable target to regulate the epithelial barrier.

Peterson R, Reed R, Zamecnik C, Sallam M, Finbloom J, Martinez F J Cell Sci. 2024; 137(24).

PMID: 39552289 PMC: 11795292. DOI: 10.1242/jcs.263580.


Precise surface functionalization of PLGA particles for human T cell modulation.

Hadley P, Chen Y, Cline L, Han Z, Tang Q, Huang X Nat Protoc. 2023; 18(11):3289-3321.

PMID: 37853157 PMC: 10775953. DOI: 10.1038/s41596-023-00887-8.


NK cell-based tumor immunotherapy.

Zhang H, Yang L, Wang T, Li Z Bioact Mater. 2023; 31:63-86.

PMID: 37601277 PMC: 10432724. DOI: 10.1016/j.bioactmat.2023.08.001.


Harnessing Biomaterials for Immunomodulatory-Driven Tissue Engineering.

Zhong J, Raghavan P, Desai T Regen Eng Transl Med. 2023; 9(2):224-239.

PMID: 37333620 PMC: 10272262. DOI: 10.1007/s40883-022-00279-6.


Bioinspired Polymeric High Aspect Ratio Particles with Asymmetric Janus Functionalities.

Finbloom J, Cao Y, Desai T Adv Nanobiomed Res. 2021; 1(5).

PMID: 33997858 PMC: 8115014. DOI: 10.1002/anbr.202000057.


References
1.
Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17(7):2105-16. DOI: 10.1200/JCO.1999.17.7.2105. View

2.
Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E . Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med. 2016; 8(367):367ra166. DOI: 10.1126/scitranslmed.aag3187. View

3.
Edwards D, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew M . Large porous particles for pulmonary drug delivery. Science. 1997; 276(5320):1868-71. DOI: 10.1126/science.276.5320.1868. View

4.
Xue J, Feng B, Zheng R, Lu Y, Zhou G, Liu W . Engineering ear-shaped cartilage using electrospun fibrous membranes of gelatin/polycaprolactone. Biomaterials. 2013; 34(11):2624-31. DOI: 10.1016/j.biomaterials.2012.12.011. View

5.
Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno B . Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat Commun. 2016; 7:12878. PMC: 5036003. DOI: 10.1038/ncomms12878. View